LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Diplomat Pharmacy, Inc. (“Diplomat” or the “Company”) (NYSE: DPLO) concerning possible violations of federal securities laws between October 9, 2014 and November 2, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm in advance of the January 9, 2017 lead plaintiff motion deadline.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, Diplomat issued false and misleading statements to investors and/or failed to disclose: that the Company lacked adequate internal controls over its financial reporting and thus could not adequately calculate DIR fees; that Diplomat’s hepatitis C segment was not performing as previously disclosed to investors; that the Company overstated its full-year 2016 guidance; and that as a result of the above, Diplomat’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On November 2, 2016, Diplomat announced third quarter 2016 results that fell below investors’ expectations. The Company also lowered full year 2016 guidance.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.